CORRECTION

A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

In the article “A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis” by J.M. Burton et al. (Neurology® 2010;74:1852–1859), in figure 2, panels A, C, and D, the vitamin D3 dose was incorrectly labeled. The corrected figure is reprinted below. The editorial staff regrets the error.

Figure 2   Serum calcium and 25(OH)D results within and between patients

(A) Mean serum calcium (mmol/L) over dosing regimen in treatment group. (B) Mean serum calcium (mmol/L) of control and treatment groups at week 1 (0 IU/day vitamin D3 for treatment group), week (10,000 IU/day of vitamin D3 for treatment group), week (40,000 IU/day of vitamin D3 for treatment group), and week (discontinuation of vitamin D3 for treatment group). (C) Urinary calcium: creatinine ratios over dosing regimen in treatment group. (D) Serum 25(OH)D (nmol/L) over dosing regimen in treatment group [the value on the y-axis reflects the mean 25(OH)D level after completing the course associated with the dose of vitamin D on the x-axis].
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

Neurology 2010;75;1029
DOI 10.1212/WNL.0b013e3181f62786

This information is current as of September 13, 2010

Updated Information & Services
including high resolution figures, can be found at:
http://www.neurology.org/content/75/11/1029.full.html

Permissions & Licensing
Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://www.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://www.neurology.org/misc/addir.xhtml#reprintsus